The evaluation of the distribution of CD133, CXCR1 and the tumor associated macrophages in different molecular subtypes of breast cancer
2020
Breast cancer has different molecular
subtypes, which determine the prognosis and response to
the treatment. CD133 is a marker for cancer stem cells in
tumor microenvironment with diagnostic/therapeutic
importance. The tumor associated macrophages (TAMs)
interact with the cancer stem cells through the CXCR1
receptor. In this study, we wanted to investigate the
expression of these markers in patients with different
molecular subtypes, in order to detect pathophysiological mechanisms and new molecular targets for the
prospective targeted therapies. In this study we
hypothesized a difference in expression of these antigens
among different subtypes. We investigated expression of
antigens in breast cancer patients with luminal A (LA),
luminal B (LB), HER2 overexpressing (HER2OE), triple
negative (TN) subtypes (n=70) and control patients
(n=10) without cancer diagnosis. We applied indirect
immunohistochemistry and evaluated immunostaining.
CD133 expression was at the periphery and CXCR1
expression was at the central area of the tumor. The
cytoplasmic CXCR1, CD133 expressions and nuclear
CD133 expression, which is prominent in the TN
subtype, were observed in patients. There was a
statistically significant difference between the groups for
CD133 (p=0.004), CXCR1 (p=0.002) H-Score values
and M2 macrophages/whole TAM ratios (p=0.022).
Between the CD133 and CXCR1 H-scores, there was a
weak positive correlation (r=0.249, p=0.035). This study
showed the compartment specific expression of the
CD133 and CXCR1 antigens in neoplastic cells. The use
of CD133 as a stem cell marker may be limited to TN
subtype, due to its heterogeneous expression.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
29
References
0
Citations
NaN
KQI